ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA (Fri, 21 Mar 2014)
<p id="p-0001" num="0000">Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.</p>
>> read more

ANTI-IL-18 ANTIBODIES AND THEIR USES (Fri, 03 Jan 2014)
<p id="p-0001" num="0000">The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.</p>
>> read more

Stabilized Angiopoietin-2 Antibodies And Uses Thereof (Fri, 25 Oct 2013)
<p id="p-0001" num="0000">Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.</p>
>> read more

Multispecific epitope binding proteins and uses thereof (Thu, 15 Aug 2013)
The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
>> read more

Binding members for IGE molecules (Thu, 01 Aug 2013)
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
>> read more

TREATMENT FOR RHEUMATOID ARTHRITIS (Fri, 19 Apr 2013)
Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate.
>> read more

BINDING MEMBERS-513 (Fri, 29 Mar 2013)
<p id="p-0001" num="0000">This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K<sub>D </sub>of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).</p>
>> read more

Stabilized anti-respiratory syncytial virus (RSV) antibody formulations (Thu, 21 Mar 2013)
The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 21 Dec 2012)
<p id="p-0001" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

ANTI-IL-18 ANTIBODIES AND THEIR USES (Fri, 29 Jun 2012)
The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.
>> read more

Antibody molecule for human GM-CSF receptor alpha (Fri, 08 Jun 2012)
<p id="p-0001" num="0000">Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.</p>
>> read more

Binding member for GM-CSF receptor (Thu, 01 Mar 2012)
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
>> read more

Binding member for GM-CSF receptor (Thu, 01 Mar 2012)
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 17 Feb 2012)
<p id="p-0001" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

ANTIBODY FORMULATIONS (Fri, 06 Jan 2012)
The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation.
>> read more

ANTIBODY FORMULATIONS (Fri, 06 Jan 2012)
The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation.</p>
>> read more

ANTIBODY FORMULATION (Fri, 21 Oct 2011)
<p id="p-0001" num="0000">The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide The formulation provides for an anti-13H5 anti-human interferon alpha antibody A pre-filled syringe containing the formulation is also disclosed.</p>
>> read more

FIBRONECTIN TYPE III DOMAIN-BASED MULTIMERIC SCAFFOLDS (Fri, 21 Oct 2011)
The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.
>> read more

FIBRONECTIN TYPE III DOMAIN-BASED MULTIMERIC SCAFFOLDS (Fri, 21 Oct 2011)
The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.</p>
>> read more

BINDING MEMBERS FOR IGE MOLECULES (Fri, 02 Sep 2011)
<p id="p-0001" num="0000">This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.</p>
>> read more

Antibodies binding to a C-terminal fragment of apolipoprotein E (Thu, 14 Jul 2011)
A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
>> read more

METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS (Fri, 01 Jul 2011)
<p id="p-0001" num="0000">The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k<sub>on</sub>) of at least 2×10<sup>5 </sup>M<sup>−1 </sup>s<sup>−1 </sup>and a dissociation rate (k<sub>off</sub>) of less than 5×10<sup>−4 </sup>s<sup>−1</sup>.</p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Thu, 02 Jun 2011)
The present invention provides liquid formulations of SYNAGIS ® or an antigen binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
>> read more

HINGE DOMAIN ENGINEERING (Fri, 01 Apr 2011)
<p id="p-0001" num="0000">The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.</p>
>> read more

Stabilized angiopoietin-2 antibodies and uses thereof (Fri, 25 Feb 2011)
<p id="p-0001" num="0000">Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.</p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 04 Feb 2011)
<p id="p-0001" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 03 Dec 2010)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.</p>
>> read more

Protein scaffolds (Fri, 26 Nov 2010)
<p id="p-0001" num="0000">The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.</p>
>> read more

IL-33 IN INFLAMMATORY DISEASE (Fri, 15 Oct 2010)
<p id="p-0001-en" num="0000">The present invention encompasses IL-33 specific binding polypeptides and compositions comprising IL-33 specific binding polypeptides, e.g., antibodies and monomer/multimer domain polypeptides. The invention also encompasses methods employing the IL-33 specific binding polypeptides to treat diseases and disorders such as asthma.</p>
>> read more

MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF (Fri, 17 Sep 2010)
<p id="p-0001-en" num="0000">The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.</p>
>> read more

Antibodies to IL-1R1 (Fri, 03 Sep 2010)
<p id="p-0001" num="0000">This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K<sub>D </sub>of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).</p>
>> read more

ANTIBODY FORMULATION (Fri, 20 Aug 2010)
<p id="p-0001-en" num="0000">The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.</p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Thu, 15 Jul 2010)
The present invention provides liquid formulations of SYNAGIS ® or an antigen binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS ® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS ® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
>> read more

ANTIBODY FORMULATION (Fri, 21 May 2010)
Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.
>> read more

ANTIBODY FORMULATION (Fri, 21 May 2010)
Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution. </p>
>> read more

BINDING MEMBERS AGAINST IL-1R1 (Sat, 15 May 2010)
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-I and IL-1Ra for binding to IL-1R1 and binds I1-1R1 with a KD of 10pM or less when measured by KinexaTM. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).
>> read more

BINDING MEMBERS AGAINST IL-1R1 (Sat, 15 May 2010)
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-I and IL-1Ra for binding to IL-1R1 and binds I1-1R1 with a KD of 10pM or less when measured by KinexaTM. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD). </p>
>> read more

Integrated approach for generating multidomain protein therapeutics (Fri, 30 Apr 2010)
<p id="p-0001" num="0000">The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.</p>
>> read more

METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS (Fri, 23 Apr 2010)
<p id="p-0001-en" num="0000">The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k<sub>on</sub>) of at least 2×10<sup>5 </sup>M<sup>−1</sup>s<sup>−1 </sup>and a dissociation rate (k<sub>off</sub>) of less than 5×10<sup>−4 </sup>s<sup>−1</sup>.</p>
>> read more

ANTIBODY FORMULATION (Fri, 16 Apr 2010)
The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide The formulation provides for an antι-13H5 anti-human interferon alpha antibody A pre-filled syringe containing the formulation is also disclosed.
>> read more

Antibodies to CXCL13 (Fri, 09 Apr 2010)
<p id="p-0001" num="0000">The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.</p>
>> read more

ANTIBODY FORMULATION (Fri, 02 Oct 2009)
The present invention provides ultra high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.
>> read more

STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF (Fri, 07 Aug 2009)
Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
>> read more

STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF (Fri, 07 Aug 2009)
Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided. </p>
>> read more

PEPTIDE MIMETICS (Fri, 24 Jul 2009)
Peptides that bind to Fcγ receptors and may or may not elicit functional activity are provided. Methods of screening, selection, manufacture, and use of such peptides are also provided.
>> read more

Stabilized anti-respiratory syncytial virus (RSV) antibody formulations (Fri, 10 Jul 2009)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.</p>
>> read more

MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF (Fri, 19 Jun 2009)
<p id="p-0001-en" num="0000">The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.</p>
>> read more

Antibody molecule for human GM-CSF receptor alpha (Fri, 22 May 2009)
<p id="p-0001" num="0000">Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.</p>
>> read more

PROTEIN SCAFFOLDS (Fri, 08 May 2009)
The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
>> read more

PROTEIN SCAFFOLDS (Fri, 08 May 2009)
The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds. </p>
>> read more

ANTIBODY MOLECULES FOR HUMAN IL-17 (Thu, 02 Apr 2009)
Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.
>> read more

Binding members for IgE molecules (Fri, 06 Mar 2009)
<p id="p-0001" num="0000">This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.</p>
>> read more

Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations (Fri, 27 Feb 2009)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α<sub>V</sub>β<sub>3</sub>, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α<sub>V</sub>β<sub>3</sub>, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α<sub>V</sub>β<sub>3</sub>, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.</p>
>> read more

MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF (Fri, 06 Feb 2009)
The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
>> read more

MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF (Fri, 06 Feb 2009)
The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. </p>
>> read more

HINGE DOMAIN ENGINEERING (Fri, 09 Jan 2009)
The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
>> read more

BINDING MEMBER FOR GM-CSF RECEPTOR (Thu, 11 Dec 2008)
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR ), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
>> read more

IL-33 IN INFLAMMATORY DISEASE (Fri, 28 Nov 2008)
The present invention encompasses IL-33 specific binding polypeptides and compositions comprising IL-33 specific binding polypeptides, e.g., antibodies and monomer/multimer domain polypeptides. The invention also encompasses methods employing the IL-33 specific binding polypeptides to treat diseases and disorders such as asthma.
>> read more

IL-33 IN INFLAMMATORY DISEASE (Fri, 28 Nov 2008)
The present invention encompasses IL-33 specific binding polypeptides and compositions comprising IL-33 spe-cific binding polypeptides, e.g., antibodies and monomer/multimer domain polypeptides. The invention also encompasses methods employing the IL-33 specific binding polypeptides to treat diseases and disorders such as asthma. </p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 21 Nov 2008)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

ANTIBODY FORMULATION (Fri, 10 Oct 2008)
The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.
>> read more

ANTIBODY FORMULATION (Fri, 10 Oct 2008)
The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.</p>
>> read more

MONOCLONAL ANTI-CXCL13 ANTIBODIES (Fri, 29 Aug 2008)
The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.
>> read more

MONOCLONAL ANTI-CXCL13 ANTIBODIES (Fri, 29 Aug 2008)
The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.</p>
>> read more

BINDING MEMBERS FOR IGE MOLECULES (Fri, 22 Aug 2008)
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
>> read more

BINDING MEMBERS FOR IGE MOLECULES (Fri, 22 Aug 2008)
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
>> read more

BINDING MEMBERS FOR IGE MOLECULES (Fri, 22 Aug 2008)
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.</p>
>> read more

BINDING MEMBERS FOR IGE MOLECULES (Fri, 22 Aug 2008)
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.</p>
>> read more

STABILIZED ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 04 Apr 2008)
The present invention provides methods of optimizing certain stable liquid formulations of antibodies that immunospecifically bind to antigens of interest. Such formulations are suitable for parenteral administration to a subject, and exhibit increased stability, low to undetectable levels of aggregation, low to undetectable levels of antibody fragmentation/degradation, and very little to no loss of the biological activities of the antibodies, even during long periods of storage. The methods of the invention provide formulations that offer multiple advantages over formulations produced by non-optimized methods, including less stringent or more readily available transportation and storage conditions, less frequent dosing, and/or smaller dosage amounts in the therapeutic, prophylactic and diagnostic uses of such formulations. The invention further provides methods of identifying antibodies exhibiting certain phase behaviors such that the antibodies can be formulated by the methods of the invention. Also provided are prophylactic, therapeutic, and diagnostic uses of such antibody formulations.
>> read more

STABILIZED ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 04 Apr 2008)
The present invention provides methods of optimizing certain stable liquid formulations of antibodies that immunospecifically bind to antigens of interest. Such formulations are suitable for parenteral administration to a subject, and exhibit increased stability, low to undetectable levels of aggregation, low to undetectable levels of antibody fragmentation/degradation, and very little to no loss of the biological activities of the antibodies, even during long periods of storage. The methods of the invention provide formulations that offer multiple advantages over formulations produced by non-optimized methods, including less stringent or more readily available transportation and storage conditions, less frequent dosing, and/or smaller dosage amounts in the therapeutic, prophylactic and diagnostic uses of such formulations. The invention further provides methods of identifying antibodies exhibiting certain phase behaviors such that the antibodies can be formulated by the methods of the invention. Also provided are prophylactic, therapeutic, and diagnostic uses of such antibody formulations.</p>
>> read more

ANTIBODY MOLECULES FOR HUMAN IL-17 (Fri, 28 Dec 2007)
Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.</p>
>> read more

BINDING MEMBER FOR GM-CSF RECEPTOR (Fri, 05 Oct 2007)
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR ), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
>> read more

BINDING MEMBER FOR GM-CSF RECEPTOR (Fri, 05 Oct 2007)
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR ), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.</p>
>> read more

EPHA2 BITE MOLECULES AND USES THEREOF (Fri, 29 Jun 2007)
The present invention relates to bispecific single chain antibodies comprising a first binding domain that irnmunospecifÊcally binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term 'EphA2-BiTEs.' The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2 -BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2 -BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents.
>> read more

EPHA2 BITE MOLECULES AND USES THEREOF (Fri, 29 Jun 2007)
The present invention relates to bispecific single chain antibodies comprising a first binding domain that irnmunospecifEcally binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term "EphA2-BiTEs." The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expres-sion and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2 -BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2-BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents. </p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 02 Mar 2007)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

AN INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTICS (Fri, 12 Jan 2007)
The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.
>> read more

AN INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTICS (Fri, 12 Jan 2007)
The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics. </p>
>> read more

Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus (Fri, 29 Sep 2006)
<p id="p-0001-en" num="0000">The invention relates to improved strains of mammalian negative strand RNA virus, <i>metapneumovirus </i>(MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further related to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections. </p>
>> read more

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS FOR PROPAGATING VIRUS (Fri, 22 Sep 2006)
The invention relates to improved strains of mammalian negative strand RNA virus, metapneumo virus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further relates to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections.
>> read more

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS FOR PROPAGATING VIRUS (Fri, 22 Sep 2006)
The invention relates to improved strains of mammalian negative strand RNA virus, metapneumo virus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further relates to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections. </p>
>> read more

Methods of preventing and treating RSV infections and related conditions (Fri, 02 Jun 2006)
<p id="p-0001-en" num="0000">The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k<sub>on</sub>) of at least 2×10<sup>5 </sup>M<sup>−1</sup>s<sup>−1 </sup>and a dissociation rate (k<sub>off</sub>) of less than 5×10<sup>−4 </sup>s<sup>−1</sup>. </p>
>> read more

METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS (Fri, 12 May 2006)
The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2 x 105 M-1s-1 and a dissociation rate (koff) of less than 5 x 10-4 S-1.
>> read more

METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS (Fri, 12 May 2006)
The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2 x 105 M-1s-1 and a dissociation rate (koff) of less than 5 x 10-4 S-1. </p>
>> read more

HIGH CELL DENSITY PROCESS FOR GROWTH OF LISTERIA (Fri, 28 Apr 2006)
The present invention relates to fed batch culture methods for high cell density growth of Listeria which produce cultures having an OD600 greater than about 2.2 or higher. In particular, the invention provides methods for high cell density growth of Listeria comprising growth in a pH controlled bioreactor and, optionally, the gradual addition of a carbon source, e.g., glucose, with or without one or more additional nutrients, e.g., vitamins, when growth in the initial culture is nearly complete or complete. In one embodiment, the methods of the invention are used to produce Listeria-based compositions, e.g., vaccines comprising Listeria that express a tumor-associated antigen, e.g., an EphA2 antigenic peptide, for eliciting an immune response against hyperproliferative cells.
>> read more

HIGH CELL DENSITY PROCESS FOR GROWTH OF LISTERIA (Fri, 28 Apr 2006)
The present invention relates to fed batch culture methods for high cell density growth of Listeria which produce cultures having an OD600 greater than about 2.2 or higher. In particular, the invention provides methods for high cell density growth of Listeria comprising growth in a pH controlled bioreactor and, optionally, the gradual addition of a carbon source, e.g., glucose, with or without one or more additional nutrients, e.g., vitamins, when growth in the initial culture is nearly complete or complete. In one embodiment, the methods of the invention are used to produce Listeria- basedcompositions, e.g., vaccines comprising Listeria that express a tumor- associated antigen, e.g., an EphA2 antigenic peptide, for eliciting an immune response against hyperproliferative cells. </p>
>> read more

Stabilized liquid anti-RSV antibody formulations (Fri, 17 Feb 2006)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.</p>
>> read more

ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 16 Dec 2005)
The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.
>> read more

ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 16 Dec 2005)
The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention. </p>
>> read more

Anti-IL-9 antibody formulations (Fri, 25 Nov 2005)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.</p>
>> read more

STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS (Thu, 26 May 2005)
The present invention provides liquid formulations of SYNAGIS<sp>®</sp> or an antigen­binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS<sp>®</sp> or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS<sp>®</sp> or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
>> read more

Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus (Fri, 28 Jan 2005)
<p id="p-0001-en" num="0000">The present invention provides an isolated mammalian negative strand RNA virus, <i>metapneumovirus </i>(MPV), within the sub-family <i>Pneumoviridae</i>, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus <i>Metapneumovirus </i>and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian <i>metapneumoviruses</i>, in particular human <i>metapneumoviruses</i>. The invention relates to the use of the sequence information of different isolates of mammalian <i>metapneumoviruses </i>for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a <i>metapneumovirus </i>or a portion thereof, including both mammalian and avian <i>metapneumovirus</i>. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian <i>metapneumovirus</i>, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. The invention also provide methods for propagating virus.</p>
>> read more

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS FOR PROPAGATING VIRUS (Fri, 12 Nov 2004)
The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. The invention also provide methods for propagating virus.
>> read more

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS FOR PROPAGATING VIRUS (Fri, 12 Nov 2004)
The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. The invention also provide methods for propagating virus. </p>
>> read more

Stabilized high concentration anti-integrin alphanubeta3 antibody formulations (Fri, 22 Oct 2004)
<p id="p-a-0001-en">The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α<sub>V</sub>β<sub>3</sub>, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α<sub>V</sub>β<sub>3</sub>, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α<sub>V</sub>β<sub>3</sub>, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention. </p>
>> read more

Uses of anti-integrin alphanubeta3 antibody formulations (Fri, 22 Oct 2004)
<p id="p-a-0001-en">The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α<sub>v</sub>β<sub>3</sub>, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α<sub>v</sub>β<sub>3</sub>, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α<sub>v</sub>β<sub>3</sub>, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention. </p>
>> read more

Stabilized immunoglobulins (Fri, 01 Oct 2004)
<p id="p-0001-en" num="0000">The present invention provides stabilized immunoglobulin molecules that have increased storage stability and/or in vivo half-lives due to the mutation of one or more amino acids that would otherwise render the immunoglobulin molecules susceptible to degradation. In a preferred embodiment, the stabilized immunoglobulins of the invention have mutations at the heavy chain constant domain hinge region. Such stabilized immunoglobulin molecules, i.e., immunoglobulin molecules with increased storage stability have one or more of the following advantages they are more readily transported and/storable for longer periods and/or less stringent conditions than non-stabilized counterparts; that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such stabilized molecules.</p>
>> read more

ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 13 Aug 2004)
The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin ανβ3 , which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin ανβ3 , which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin ανβ3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.
>> read more

ANTI-INTEGRIN .ALPHA..NU..BETA.3 ANTIBODY FORMULATIONS AND USES THEREOF (Fri, 13 Aug 2004)
The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin .alpha..nu..beta.3 , which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin .alpha..nu..beta.3 , which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin .alpha..nu..beta.3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention. </p>
>> read more

Stabilized anti-respiratory syncytial virus (RSV) antibody formulations (Fri, 30 Jan 2004)
<p id="p-0001-en" num="0000">The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.</p>
>> read more

STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS (Thu, 25 Dec 2003)
The present invention provides liquid formulations of SYNAGIS® or an antigen­binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
>> read more

STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS (Thu, 25 Dec 2003)
The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
>> read more

STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS (Thu, 25 Dec 2003)
The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifcally bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention. </p>
>> read more

STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS (Thu, 25 Dec 2003)
The present invention provides liquid formulations of SYNAGIS® or an antigen~binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. </p>
>> read more

Thermally stable trimetrexates and processes for producing the same (Fri, 24 Oct 2003)
<p id="p-a-0001-en">The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)}(#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form. </p>
>> read more

RECOMBINANT ANTI-INTERLEUKIN-9 ANTIBODIES (Fri, 24 Oct 2003)
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL- 9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1. </p>
>> read more

Tremextrexate derivatives and pharmaceutical compositions comprising the same (Fri, 09 Aug 2002)
<p id="p-a-0001-en">The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)} (#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form. </p>
>> read more

F-PROTEIN EPITOPE-BASED VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS INFECTION (Fri, 30 Nov 2001)
The present invention relates to a vaccine that comprises selected epitopes within the F protein structure that have been proven to specifically interact with known potent neutralizing antibodies while simultaneously being presented as part of a synthetic structure that offers these epitopes apart from the other non-neutralizing antigenic determinants of the virus but held in a native conformational form and thereby capable of eliciting neutralizing antibodies.
>> read more

Thermally stable trimetrexates and processes for producing the same (Wed, 11 Jul 2001)
<p id="p-00001-en">The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)}(#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.</p>
>> read more

Site Search